Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection. Academic Article uri icon

Overview

abstract

  • The Lassa virus is endemic in parts of West Africa, and it causes hemorrhagic fever with high mortality. The development of a recombinant protein vaccine has been hampered by the instability of soluble Lassa virus glycoprotein complex (GPC) trimers, which disassemble into monomeric subunits after expression. Here, we use two-component protein nanoparticles consisting of trimeric and pentameric subunits to stabilize GPC in a trimeric conformation. These GPC nanoparticles present twenty prefusion GPC trimers on the surface of an icosahedral particle. Cryo-EM studies of GPC nanoparticles demonstrated a well-ordered structure and yielded a high-resolution structure of an unliganded GPC. These nanoparticles induced potent humoral immune responses in rabbits and protective immunity against the lethal Lassa virus challenge in guinea pigs. Additionally, we isolated a neutralizing antibody that mapped to the putative receptor-binding site, revealing a previously undefined site of vulnerability. Collectively, these findings offer potential approaches to vaccine and therapeutic design for the Lassa virus.

publication date

  • November 17, 2022

Research

keywords

  • Lassa Fever
  • Nanoparticles

Identity

PubMed Central ID

  • PMC9794196

Scopus Document Identifier

  • 85143512375

Digital Object Identifier (DOI)

  • 10.1016/j.chom.2022.10.018

PubMed ID

  • 36400021

Additional Document Info

volume

  • 30

issue

  • 12